State AGs And Former DEA Leaders Push Agency To Hold Public Hearing On Marijuana Rescheduling Proposal
North Carolina Senate Gives Initial Approval To Bill That Would Legalize Medical Marijuana In Rebuke Of House Opposition
Biden ‘Commends And Welcomes’ Maryland Governor’s Mass Marijuana Pardon, White House Says
Pennsylvania Could See Up To $2.8 Billion In Marijuana Sales In First Year Of Legalization And Create 45,000 Jobs, Analysis Finds
Minnesota Lawmakers Codify Court Decision Ending Marijuana Odor As Justification For Vehicle Searches
Older Patients Using Medical Cannabis ‘Experience Considerable Improvement In Health And Well-Being,’ Study Finds
Youth See Reddit As ‘Viable Outlet’ For Marijuana Info, But Posts Often Have ‘Lack Of Verifiable’ Facts, Study Finds
People’s Use Of Alcohol Or Opioids Causes Greater Secondhand Harms Than Marijuana Consumption Does, Study Finds
Youth Marijuana Use In Colorado Continues To Decline Since Legalization Took Effect, Contradicting Prohibitionist Fears
Communities Closer To Marijuana Dispensaries Have Lower Opioid Prescription Rates, New Study Finds
California State Fair Will Allow Marijuana Sales And On-Site Consumption For First Time
Marijuana Rolling Paper Company Will Pay $4.20 To Volunteers To ‘Smoke Joints For Science’
NFL Sued By Player Who Was Fined Over $500,000 For Positive THC Tests Caused By Prescribed Cannabis Medication
Brands And Advocacy Groups—From ACLU To KFC—Launch 4/20 Promotions To Mark The Marijuana Holiday
Former Minnesota Gov. Jesse Ventura Promotes New Cannabis Brand Ahead Of 4/20 That He’d ‘Offer To You’ On Governor’s Mansion Visit
Oregon’s First-In-Nation Psilocybin Industry Is Struggling To Find Paying Customers A Year After Launching
States Have Generated Over $20 Billion In Marijuana Tax Revenue Since First Markets Opened, New Report Finds
Arkansas Medical Marijuana Dispensary Gets License Revoked Over Alleged Violations
New Jersey Set A New Marijuana Sales Record Last Quarter, With Regulators Touting ‘Historical Highs’ On 4/20 Weekend
Massachusetts Saw Record-Breaking Marijuana Sales On 4/20, Pushing State Across $6 Billion Mark For Recreational Purchases
Biden ‘Commends And Welcomes’ Maryland Governor’s Mass Marijuana Pardon, White House Says
Maryland Governor Pledges To Work With Lawmakers On Marijuana Expungements To Build On His Mass Pardon Move
New York Governor Links Illicit Marijuana Shop Crackdown To ‘Dramatically’ Increased Legal Sales, As Equity-Focused Activists Protest Administration
Marijuana Rescheduling Opponents Slam FDA Process, Saying It Relied On ‘Very Bad Studies’
Maryland Governor Pardons More Than 175,000 Marijuana And Paraphernalia Convictions
Pennsylvania cannabis legalization has enough votes to pass, senators say (Newsletter: June 20, 2024)
Calif. State Fair to allow cannabis use & sales on site (Newsletter: June 19, 2024)
Maryland governor issues mass cannabis pardons (Newsletter: June 18, 2024)
Cannabis testing ban for military recruits passes House (Newsletter: June 17, 2024)
Cannabis banking setback in Congress (Newsletter: June 14, 2024)
Published
on
By
A Drug Enforcement Administration (DEA) official says the agency wants to “correct misperceptions” that its drug scheduling review process is done in a “shroud of secrecy” as it works to reach a final decision on possibly reclassifying marijuana. He also said it sometimes takes up to six months for DEA to complete its analysis of health officials’ recommendations—which is just about how long it has now been since the agency began its current cannabis assessment.
In the latest episode of the agency’s “Prevention Profiles: Take Five” series, DEA Senior Prevention Program Manager Rich Lucey spoke with DEA pharmacologist Buki Ebeigbe about the scheduling process and specifically how it relates to the ongoing cannabis review—marking the first time that officials with the agency have discussed its current analysis of marijuana’s Schedule I status publicly in any depth.
“I just think it’s important for people to—again, going back to correcting misperceptions and really the issue of transparency and, by us even doing this podcast, just to help people understand the process,” Lucey said. “We don’t want it to necessarily feel as if it’s behind this shroud of secrecy, which I think then lends itself to this idea that it’s a whole arbitrary process.”
Transparency has been a key concern for advocates and lawmakers, with DEA declining to say anything publicly beyond confirming that they’ve received the recommendation from the U.S. Department of Health and Human Services (HHS) to move marijuana from Schedule I to Schedule III of the Controlled Substances Act (CSA) and are now carrying out their own review.
That process is “independent” of the HHS review, Lucey stressed.
That’s right,” Ebeigbe said. “It’s in its process. We’ve received [the HHS analysis], and we’re in the process of writing that recommendation” on cannabis scheduling to DEA Administrator Anne Milgram.
“Once that information is compiled and that document is written—that eight-factor document is written—it’s reviewed through our internal process,” she said, referring to the multi-step analysis the agency is completing on the effects of cannabis. “Ultimately, the administrator will make a decision on where to place it—whether to change it or whether to remove it or whatever.”
Lucey also commented on the complexity of drug scheduling reviews and what that means in terms of timing.
“Right now it’s a ‘wait and see.’ HHS has done their part, and now DEA is doing its part, which is that eight-factor analysis. And that can take anywhere from like three to six months sometimes,” he said. “I mean, it’s not like we’re going to be done in a week. It never happens that way.”
While Lucey was speaking generally about the drug scheduling review process, that timeline is notable. HHS delivered its Schedule III recommendation to DEA last August, meaning it’s been more than six months now that the drug agency has been conducting its own review. And there’s significant pressure to complete its work expeditiously.
🎙️ WATCH #DEACampus podcast Prevention Profiles: Take Five! w/ guest Dr. Buki Ebeigbe, a DEA Diversion Control Division pharmacologist. Discover insights into the Controlled Substances Act, common misperceptions, and her journey into DEA.
Tune in now: https://t.co/Gz97J1IRKT pic.twitter.com/yrUFO4YjUP
— DEA HQ (@DEAHQ) March 27, 2024
Vice President Kamala Harris recently added her voice to that end, urging DEA to finalize its cannabis review “as quickly as possible” and calling it “absurd” and “patently unfair” that marijuana remains in Schedule I alongside drugs such as heroin.
The expectation is that, once DEA completes the review, it will publish its decision in the Federal Register, after which point there will be a public comment period. Asked whether those comments will “play a role” in the possibility of rescheduling, Ebeigbe said “that is an unknown—that is an absolute unknown.”
In any case, she stressed earlier in the interview that “it’s important for the viewers to know that we read every single comment and we have to respond publicly.” She also noted that, after the public comment period, there’s a possibility the agency will schedule a hearing, which individuals can request if they “would like their opinions heard on a larger scale.”
Ebeigbe also broadly defended the scheduling review process, stressing that it is not “arbitrary” and that everything the agency does must be “legally defensible.”
One legal question that may be considered concerns international treaty obligations and whether the U.S. would be out of compliance with United Nations (UN) Single Convention treaties if it moved cannabis to Schedule III—an argument that several conservative lawmakers and prohibitionists have insisted DEA take into account, despite differing opinions among legal experts.
Meanwhile, HHS Secretary Xavier Becerra recently defended his agency’s rescheduling recommendation during a Senate committee hearing and also told cannabis lobbyist Don Murphy that he should pay DEA a visit and “knock on their door” for answers about the timing of their decision.
Certain DEA officials are reportedly resisting the Biden administration’s rescheduling push, disputing the HHS findings on marijuana’s safety profile and medical potential, according to unnamed sources who spoke with The Wall Street Journal.
The Biden administration was also recently pressed to reschedule marijuana by two coalitions representing military veterans and law enforcement—including a group that counts DEA’s Milgram among its members.
Based on a recent poll, President Joe Biden’s cannabis moves stand to benefit him in the election. The survey found the president’s favorability spiked after people were made aware of the possibility that marijuana could be rescheduled under the Biden-initiated review.
Where Presidential Candidate Donald Trump Stands On Marijuana
Photo courtesy of Mike Latimer.
Maryland Legislative Committees Approve Psychedelics Task Force Bills That Already Passed Full Opposite Chambers
Vermont Senate Passes Psychedelic Working Group Bill To Study How Entheogens Might Benefit Physical And Mental Health
Kyle Jaeger is Marijuana Moment’s Sacramento-based managing editor. His work has also appeared in High Times, VICE and attn.
State AGs And Former DEA Leaders Push Agency To Hold Public Hearing On Marijuana Rescheduling Proposal
North Carolina Senate Gives Initial Approval To Bill That Would Legalize Medical Marijuana In Rebuke Of House Opposition
Biden ‘Commends And Welcomes’ Maryland Governor’s Mass Marijuana Pardon, White House Says
Pennsylvania Could See Up To $2.8 Billion In Marijuana Sales In First Year Of Legalization And Create 45,000 Jobs, Analysis Finds
Minnesota Lawmakers Codify Court Decision Ending Marijuana Odor As Justification For Vehicle Searches
Older Patients Using Medical Cannabis ‘Experience Considerable Improvement In Health And Well-Being,’ Study Finds
All the cannabis news you need, all in one place. Copyright © 2017-2024 Marijuana Moment LLC ® and Tom Angell
DEA Officials Discuss Marijuana Scheduling Timeline, Seeking To 'Correct Misperceptions' That Decisions Are Made In … – Marijuana Moment
